Investors seeking stocks that can produce dramatic gains in 2024 can find what they're looking for in the biopharmaceutical industry. Clinical-trial results that these two companies are expected to announce soon could cause these biotech stocks to rocket higher.

While big, incoming catalysts could push these stock prices higher, there is also a lot that can go wrong. Here are a few things you want to know about the opportunities and challenges ahead of these drugmakers before taking any risks of your own.

Sales of cystic fibrosis treatments from Vertex Pharmaceuticals (NASDAQ: VRTX) are on pace to pass $10 billion annually, but investors want to see the company expand beyond an indication that only affects around 105,000 people globally.

Continue reading

Source Fool.com